@article{10.11648/j.ijpc.20220805.11,
  author = {Qiu Ju Lyu and Qiang Hong Pu},
  title = {Efficacy and Safety of Hybrid Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Head-to-Head Randomized Clinical Trials},
  journal = {International Journal of Pharmacy and Chemistry},
  volume = {8},
  number = {5},
  pages = {48-56},
  doi = {10.11648/j.ijpc.20220805.11},
  url = {https://doi.org/10.11648/j.ijpc.20220805.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijpc.20220805.11},
  abstract = {Background: The efficacy and safety of hybrid therapy as the empirical first-line therapy was still unclear in Helicobacter pylori (H. pylori) infection, so the efficacy and safety of hybrid therapy was evaluated which was compared to the other eradication therapies in guidelines. Methods: PubMed, Embase, Cochrane Central Register of Controlled Trials, Wanfang and Chinese BioMedical Literature database (CBM) were searched up to February 2020. Head-to-head randomized controlled trials were included that assessed efficacy and safety of hybrid therapy compared with other therapies (standard triple therapy, concomitant therapy, bismuth quadruple therapy or sequential therapy). Statistical analysis was performed with RevMan software 5.3. Results: Ten studies (2941 participants) as first-line treatment for H. pylori were identified. In the same proton pump inhibitors and duration, H. pylori eradication rate of hybrid therapy was higher than that of standard triple therapy (pooled eradication rates, 94.2% vs 85.4%; OR, 2.68; 95%CI: [1.42–5.06], P0.05). However, there were no significant differences of eradication rates between hybrid therapy and sequential therapy (pooled eradication rates, 82.7% vs 84.9%; OR, 0.97; 95%CI: [0.85–1.11], P>0.05), concomitant therapy (pooled eradication rates, 83.5% vs 84.1%; OR, 0.96; 95%CI: [0.66–1.40], P>0.05), or bismuth quadruple therapy (pooled eradication rates, 95.2% vs 94.0%; OR, 1.28; 95%CI: [0.70–2.34], P>0.05). No significant differences in overall adverse events were found among hybrid therapy and standard triple therapy, sequential therapy, concomitant therapy or bismuth quadruple therapy. Conclusions: Hybrid therapy could be a suitable alternative to sequential therapy, concomitant therapy and bismuth quadruple therapy in first-line regimens. Hybrid therapy should be then recommended as empirical first-line regimen in H. pylori eradication.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Efficacy and Safety of Hybrid Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Head-to-Head Randomized Clinical Trials
AU  - Qiu Ju Lyu
AU  - Qiang Hong Pu
Y1  - 2022/10/11
PY  - 2022
N1  - https://doi.org/10.11648/j.ijpc.20220805.11
DO  - 10.11648/j.ijpc.20220805.11
T2  - International Journal of Pharmacy and Chemistry
JF  - International Journal of Pharmacy and Chemistry
JO  - International Journal of Pharmacy and Chemistry
SP  - 48
EP  - 56
PB  - Science Publishing Group
SN  - 2575-5749
UR  - https://doi.org/10.11648/j.ijpc.20220805.11
AB  - Background: The efficacy and safety of hybrid therapy as the empirical first-line therapy was still unclear in Helicobacter pylori (H. pylori) infection, so the efficacy and safety of hybrid therapy was evaluated which was compared to the other eradication therapies in guidelines. Methods: PubMed, Embase, Cochrane Central Register of Controlled Trials, Wanfang and Chinese BioMedical Literature database (CBM) were searched up to February 2020. Head-to-head randomized controlled trials were included that assessed efficacy and safety of hybrid therapy compared with other therapies (standard triple therapy, concomitant therapy, bismuth quadruple therapy or sequential therapy). Statistical analysis was performed with RevMan software 5.3. Results: Ten studies (2941 participants) as first-line treatment for H. pylori were identified. In the same proton pump inhibitors and duration, H. pylori eradication rate of hybrid therapy was higher than that of standard triple therapy (pooled eradication rates, 94.2% vs 85.4%; OR, 2.68; 95%CI: [1.42–5.06], P0.05). However, there were no significant differences of eradication rates between hybrid therapy and sequential therapy (pooled eradication rates, 82.7% vs 84.9%; OR, 0.97; 95%CI: [0.85–1.11], P>0.05), concomitant therapy (pooled eradication rates, 83.5% vs 84.1%; OR, 0.96; 95%CI: [0.66–1.40], P>0.05), or bismuth quadruple therapy (pooled eradication rates, 95.2% vs 94.0%; OR, 1.28; 95%CI: [0.70–2.34], P>0.05). No significant differences in overall adverse events were found among hybrid therapy and standard triple therapy, sequential therapy, concomitant therapy or bismuth quadruple therapy. Conclusions: Hybrid therapy could be a suitable alternative to sequential therapy, concomitant therapy and bismuth quadruple therapy in first-line regimens. Hybrid therapy should be then recommended as empirical first-line regimen in H. pylori eradication.
VL  - 8
IS  - 5
ER  - 

Copy | Download